专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明授权

US6143509A Prostate specific antigen peptides and uses thereof 失效
标题翻译：前列腺特异性抗原肽及其用途
公开(公告)号：US6143509A
公开(公告)日：2000-11-07
申请号：US595945
申请日：1996-02-06
申请人： Barry Lee Dowell , Dominique P. Bridon , Xiaoxing Qiu , Hans Lilja , Timo Petteri Piironen , Mauno Antero Vihinen , Kim Sverker Immanuel Pettersson
发明人： Barry Lee Dowell , Dominique P. Bridon , Xiaoxing Qiu , Hans Lilja , Timo Petteri Piironen , Mauno Antero Vihinen , Kim Sverker Immanuel Pettersson
IPC分类号： C07K7/08 , C07K14/47 , C07K16/18 , C07K16/40 , C12N9/64 , C12N15/57 , C12P21/08 , G01N33/53 , G01N33/574 , G01N33/577 , C07K16/00 , G01N33/48
CPC分类号： C12N9/6445 , C07K16/40 , Y10S435/81
摘要： The present invention relates to peptides which may be used, for example, in the detection of free and complexed Prostate Specific Antigen and thus in the diagnosis of prostate cancer.
摘要翻译：本发明涉及可用于例如游离和复合的前列腺特异性抗原的检测并因此用于诊断前列腺癌的肽。

42. 发明授权

US5843450A Hepatitis GB Virus synthetic peptides and uses thereof 失效
标题翻译：乙型肝炎病毒合成肽及其用途
公开(公告)号：US5843450A
公开(公告)日：1998-12-01
申请号：US473475
申请日：1995-06-07
申请人： George J. Dawson , Tami J. Pilot-Matias , Dominique P. Bridon , Pamella A. Schroeder-Poliak , Mark F. Knigge , Keeve D. Jaffe , Isa K. Mushahwar
发明人： George J. Dawson , Tami J. Pilot-Matias , Dominique P. Bridon , Pamella A. Schroeder-Poliak , Mark F. Knigge , Keeve D. Jaffe , Isa K. Mushahwar
IPC分类号： G01N33/53 , A61K38/00 , A61K39/00 , A61K39/395 , C07K14/005 , C07K14/02 , C07K14/10 , C07K14/18 , C07K16/00 , C07K16/08 , C07K16/10 , C12N15/09 , C12P21/02 , C12P21/08 , C12Q1/70 , G01J3/453 , G01N33/576 , A61K39/12
CPC分类号： C07K14/005 , C07K16/109 , C12Q1/707 , G01N33/576 , A61K38/00 , A61K39/00 , C07K2319/00 , C12N2770/24222 , C12N2770/36022 , Y10S436/82 , Y10S977/918
摘要： Hepatitis GB Virus (HGBV) synthetic peptides useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV peptides.
摘要翻译：可用于各种诊断和治疗应用的乙型肝炎病毒（HGBV）合成肽，使用HGBV核酸或氨基酸序列的试剂盒和特异性结合HGBV的抗体。还提供了用于从HGBV肽产生抗体，多克隆或单克隆抗体的方法。

43. 发明授权

US5800983A Peptides for HIV-1 detection 失效
标题翻译：用于HIV-1检测的肽
公开(公告)号：US5800983A
公开(公告)日：1998-09-01
申请号：US837732
申请日：1997-04-22
申请人： Dominique P. Bridon , Isaac S.-Y. Sze, deceased , David J. Daghfal , Keeve D. Jaffe , Tracey L. Colpitts
发明人： Dominique P. Bridon , Isaac S.-Y. Sze, deceased , David J. Daghfal , Keeve D. Jaffe , Tracey L. Colpitts
IPC分类号： G01N33/569 , C07K14/16 , C12Q1/70
CPC分类号： C07K14/005 , C12N2740/16122 , Y10S435/974 , Y10S435/975 , Y10S530/806 , Y10S530/812 , Y10S530/826
摘要： HIV-1 peptides having at least one point mutation between position 593 and 611 of the HIV-1 gp160 amino acid sequence. The point mutation either is at position 604 or 610, or both positions. Immunoassays which utilize these peptides are provided, as well as, diagnostic test kits which contain these peptides.
摘要翻译： HIV-1肽在HIV-1 gp160氨基酸序列的位置593和611之间具有至少一个点突变。点突变处于位置604或610，或两个位置。提供利用这些肽的免疫测定，以及包含这些肽的诊断测试试剂盒。

44. 发明授权

US08093206B2 Methods involving long lasting synthetic exendin-4 peptide conjugates 失效
标题翻译：涉及长效合成毒蜥外泌肽-4肽缀合物的方法
公开(公告)号：US08093206B2
公开(公告)日：2012-01-10
申请号：US11304446
申请日：2005-12-14
申请人： Dominique P. Bridon , Benoit L'Archeveque , Darren L. Holmes , Anouk Leblanc , Serge St. Pierre
发明人： Dominique P. Bridon , Benoit L'Archeveque , Darren L. Holmes , Anouk Leblanc , Serge St. Pierre
IPC分类号： A61K38/22
CPC分类号： C07K14/005 , A61K38/00 , A61K47/643 , C07K14/57563 , C07K14/605 , C12N2740/16122
摘要： Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
摘要翻译：公开了改进的促胰岛素肽。修饰的促胰岛素肽能够形成肽酶稳定的促胰岛素肽。修饰的促胰岛素肽能够与一种或多种血液成分形成共价键以形成缀合物。缀合物可以在体内或离体形成。施用修饰的肽以治疗患有糖尿病和其他相关疾病的人。

45. 发明授权

US08084414B2 Methods involving long lasting synthetic exendin-4-peptide conjugates 失效
标题翻译：涉及长效合成毒蜥外泌肽-4肽共轭物的方法
公开(公告)号：US08084414B2
公开(公告)日：2011-12-27
申请号：US11215967
申请日：2005-08-30
申请人： Dominique P. Bridon , Benoit L'Archeveque , Darren L. Holmes , Anouk Leblanc , Serge St. Pierre
发明人： Dominique P. Bridon , Benoit L'Archeveque , Darren L. Holmes , Anouk Leblanc , Serge St. Pierre
IPC分类号： A61K38/22
CPC分类号： C07K14/005 , A61K38/00 , A61K47/643 , C07K14/57563 , C07K14/605 , C12N2740/16122
摘要： Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
摘要翻译：公开了改进的促胰岛素肽。修饰的促胰岛素肽能够形成肽酶稳定的促胰岛素肽。修饰的促胰岛素肽能够与一种或多种血液成分形成共价键以形成缀合物。缀合物可以在体内或离体形成。施用修饰的肽以治疗患有糖尿病和其他相关疾病的人。

46. 发明申请

US20090175821A1 Modified therapeutic peptides with extended half-lives in vivo 审中-公开
标题翻译：体内延长半衰期的修饰治疗肽
公开(公告)号：US20090175821A1
公开(公告)日：2009-07-09
申请号：US11982033
申请日：2007-10-31
申请人： Dominique P. Bridon , Alan M. Ezrin , Peter G. Milner , Darren L. Holmes , Karen Thibaudeau
发明人： Dominique P. Bridon , Alan M. Ezrin , Peter G. Milner , Darren L. Holmes , Karen Thibaudeau
IPC分类号： A61K38/38 , C07K19/00 , A61K38/21 , A61K38/28 , A61K38/22 , A61K38/18
CPC分类号： C07K14/57563 , A61K38/38 , A61K47/62 , A61K47/643
摘要： A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.
摘要翻译：描述了一种在体内保护肽免受肽酶活性的方法，所述肽由2-50个氨基酸组成且具有C末端和N末端以及C末端氨基酸和N-末端氨基酸。在该方法的第一步中，通过将反应性基团连接到C末端氨基酸，N末端氨基酸或位于N末端和C末端之间的氨基酸来修饰肽，使得修饰的肽能够在体内与血液成分上的反应性官能团形成共价键。在下一步骤中，在反应性基团和血液成分上的反应性官能团之间形成共价键以形成肽 - 血液成分缀合物，从而保护所述肽免受肽酶活性。该方法的最后步骤包括分析肽 - 血液成分缀合物的稳定性，以评估肽对肽酶活性的保护。

47. 发明授权

US07166695B2 Affinity markers for human serum albumin 失效
标题翻译：人血清白蛋白的亲和标记
公开(公告)号：US07166695B2
公开(公告)日：2007-01-23
申请号：US10934841
申请日：2004-09-02
申请人： Alexander Krantz , Wolin Huang , Arthur M. Hanel , Darren L. Holmes , Dominique P. Bridon
发明人： Alexander Krantz , Wolin Huang , Arthur M. Hanel , Darren L. Holmes , Dominique P. Bridon
IPC分类号： C07K7/06
CPC分类号： A61K49/0021 , A61K38/00 , A61K47/62 , A61K47/6901 , A61K49/0043 , A61K49/0056 , C07K14/665
摘要： Methods and compositions are provided for identifying compounds having affinity or complementarity to a target molecule. Compounds according to the invention may be described by the formula E-Ca—R—Cb-A, wherein E is a therapeutic or diagnostic agent, R is a reactive group, Ca and Cb are connector groups between E and R and between R and A, respectively, and A is an affinity group comprising the sequence F-1-Y-E-E. Compounds according to the invention may be used for labeling the target molecule, particularly where the target molecule is naturally found in a complex mixture, such as a physiological fluid, like blood. By affinity labeling in vivo, the lifetime of physiologically active entities can be greatly enhanced by becoming bound to long-lived blood components. The covalently bound entity may also serve as an antagonist or agonist of a particular binding protein or as an enzyme inhibitor.
摘要翻译：提供了用于鉴定与靶分子具有亲和力或互补性的化合物的方法和组合物。根据本发明的化合物可以用下式描述：其中E是治疗剂或诊断剂，R是反应性基团，C < 分别是E和R之间以及R和A之间的连接器组，A是包含序列F-1 -YEE的亲和基团。根据本发明的化合物可以用于标记靶分子，特别是当目标分子天然存在于复杂混合物如生理液体如血液中时。通过体内亲和标记，生理活性实体的寿命可以通过与长寿命的血液成分结合而大大增强。共价结合的实体也可以用作特异性结合蛋白的拮抗剂或激动剂或作为酶抑制剂。

48. 发明授权

US06849714B1 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components 失效
标题翻译：通过与血液成分缀合，保护内源性治疗肽免受肽酶活性的影响
公开(公告)号：US06849714B1
公开(公告)日：2005-02-01
申请号：US09623548
申请日：2000-05-17
申请人： Dominique P. Bridon , Alan M. Ezrin , Peter G. Milner , Darren L. Holmes , Karen Thibaudeau
发明人： Dominique P. Bridon , Alan M. Ezrin , Peter G. Milner , Darren L. Holmes , Karen Thibaudeau
IPC分类号： A61K38/00 , C07K1/107 , C07K17/00
CPC分类号： C07K1/1077 , A61K38/00 , Y02P20/55
摘要： A method of synthesizing a modified therapeutic peptide capable of forming a peptidase-stabilized therapeutic peptide conjugate, the peptide having between 3 and 50 amino acids, is k. In a first step of the method, a therapeutic peptide having a carboxy terminal amino acid and amino terminal amino acid is synthesized. In a second step, pairs of cysteine residues present in the therapeutic peptide are sequentially and selectively oxidized to form disulfide bridges in the therapeutic peptide. In a third step, a protecting group is attached to remaining cysteine residues that do not form disulfide bridges in the therapeutic peptide. Finally, the peptide is coupled to a reactive group capable of reacting with amino groups, hydroxyl groups or thiol groups on a blood component to form a covalent bond therewith.
摘要翻译：描述了能够形成肽酶稳定的治疗性肽缀合物的修饰的治疗肽的方法，所述肽具有3至50个氨基酸。在该方法的第一步中，合成具有羧基末端氨基酸和氨基末端氨基酸的治疗肽。在第二步中，存在于治疗肽中的成对的半胱氨酸残基被顺序地和选择性氧化，以在治疗肽中形成二硫键。在第三步中，将保护基连接到在治疗肽中不形成二硫键的剩余半胱氨酸残基。最后，肽与能够与血液成分上的氨基，羟基或硫醇基反应以形成与其共价键的反应性基团偶联。

49. 发明授权

US06821949B2 Long lasting synthetic glucagon-like peptide (GLP-1) 失效
标题翻译：长效合成胰高血糖素样肽（GLP-1）
公开(公告)号：US06821949B2
公开(公告)日：2004-11-23
申请号：US10287892
申请日：2002-11-04
申请人： Dominique P. Bridon , Benoit L'Archeveque , Alan M. Ezrin , Darren L. Holmes , Anouk Leblanc , Serge St. Pierre
发明人： Dominique P. Bridon , Benoit L'Archeveque , Alan M. Ezrin , Darren L. Holmes , Anouk Leblanc , Serge St. Pierre
IPC分类号： A61K3800
CPC分类号： C07K14/005 , A61K38/00 , A61K47/643 , C07K14/57563 , C07K14/605 , C12N2740/16122
摘要： Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
摘要翻译：公开了改进的促胰岛素肽。修饰的促胰岛素肽能够形成肽酶稳定的促胰岛素肽。修饰的促胰岛素肽能够与一种或多种血液成分形成共价键以形成缀合物。缀合物可以在体内或离体形成。施用修饰的肽以治疗患有糖尿病和其他相关疾病的人。

50. 发明授权

US06610825B2 Method for alleviating pain or providing an analgesic effect in a patient 失效
标题翻译：减轻疼痛或在患者中提供镇痛作用的方法
公开(公告)号：US06610825B2
公开(公告)日：2003-08-26
申请号：US09798119
申请日：2001-03-01
申请人： Alan M. Ezrin , Dominique P. Bridon , Darren L. Holmes , Peter G. Milner
发明人： Alan M. Ezrin , Dominique P. Bridon , Darren L. Holmes , Peter G. Milner
IPC分类号： C07K700
CPC分类号： C07K14/70 , A61K38/00 , A61K47/64 , C07K14/665 , C07K2319/00
摘要： Conjugates are prepared from antinociceptive agents, particularly opioids or opioid analogs, more particularly dynorphins, endorphins, deltorphins, enkephalins or analogs thereof, by combining said antinociceptive agent with a material providing a functionally reactive group capable of reacting with a blood component (preferably a blood cell or protein). Said conjugates permit extension of the therapeutic life of the antinociceptive agent. They may be administered to patients to alleviate pain, produce analgesic effects, or assist in cases of narcotics withdrawal, and may also be used as probes for receptor activity. The administration to the patient may be made either in vivo or ex vivo and may be performed by either introducing the derivative including the reactive functional group into the patient's vascular system or preparing such a conjugate externally (or in vitro) and introducing that conjugate to the patient's vascular system.
摘要翻译：通过将所述抗伤害感受剂与提供能够与血液成分（优选血液）反应的功能反应性基团的材料组合，由抗伤害感受剂，特别是阿片样物质或阿片样物质类似物，更具体地说是强啡肽，内啡肽，delphphins，脑啡肽或其类似物制备缀合物细胞或蛋白质）。所述缀合物允许延长抗伤害感受剂的治疗寿命。可以向患者施用以缓解疼痛，产生镇痛作用或辅助麻醉药物撤出的情况，也可用作受体活性的探针。对患者的施用可以在体内或体外制备，并且可以通过将包含反应性官能团的衍生物引入患者的血管系统或者在外部（或体外）中制备这种缀合物并将该缀合物引入到患者血管系统。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式